Skip to main content
. 2022 Mar 2;55(1):291–303. doi: 10.4143/crt.2022.017

Fig. 1.

Fig. 1

The detection of plasma ctDNA mutations from 94 baseline samples and mutation profiles of plasma cell-free DNA in 53 patients with peripheral T-cell lymphoma obtained from the baseline samples of our prospective cohort. (A) The detection rate of somatic mutations was highest in two subtypes: AITL (24/31, 77%) and PTCL-NOS (18/29, 62.1%). The ctDNA mutation was detected more frequently in the groups with TFH lymphomas (70%, 28/40) and peripheral T-cell lymphomas (58%, 19/33) than in those with systemic ALCL (44%, 4/9) and cutaneous lymphomas (17%, 2/12). (B) Somatic mutations in RHOA, CREBBP, KMT2D, TP53, and IDH2 were most common across the subtypes. A red box represents the detected mutation of each gene. AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; CTCL, cutaneous T-cell lymphoma; ctDNA, circulating tumor DNA; FTCL, follicular helper T-cell lymphoma; MEITL, monomorphic epitheliotropic intestinal T-cell lymphoma; MF, mycosis fungoides; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; PTFH, peripheral T-cell lymphoma with T follicular helper type; SPTCL, subcutaneous panniculitis-like T-cell lymphoma; TFH, T follicular helper cell.